Biotech News
Related news
GANXGain Therapeutics2026-09-17 11:00 EST
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
TNXPTonix Pharmaceuticals2026-09-02 11:00 EST
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
HRMYHarmony Biosciences2026-08-27 12:05 EST
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
CGTXCognition Therapeutics2026-09-08 11:30 EST
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
NBIXNeurocrine Biosciences2026-09-02 20:01 EST
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
ABOSAcumen Pharmaceuticals2026-07-07 11:30 EST
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026
VYGRVoyager Therapeutics2026-06-11 20:01 EST
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
KTTAPasithea Therapeutics2026-09-03 20:05 EST
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
HRMYHarmony Biosciences2026-09-03 12:05 EST
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
KTTAPasithea Therapeutics2026-07-21 11:00 EST
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
Xenon
Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling. Azetukalner Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing....
Recent company news
XENEXenon2026-09-17 20:01 EST
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
XENEXenon2026-09-03 20:01 EST
Xenon to Present at Wells Fargo Healthcare Conference
XENEXenon2026-08-28 20:01 EST
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
XENEXenon2026-08-26 20:01 EST
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
XENEXenon2026-08-06 20:01 EST
Xenon Reports Q2 2026 Financial Results and Provides Business Update
Stock data
- Close
- 57.35 USD
- Market cap
- 5.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States